HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

B-Cell Leukemia (Leukemia, B Cell)

A malignant disease of the B-LYMPHOCYTES in the bone marrow and/or blood.
Also Known As:
Leukemia, B Cell; Leukemia, B-Cell; Leukemia, Lymphocytic, B Cell; B Cell Leukemia; B Lymphocytic Leukemia; B-Cell Leukemias; B-Cell Lymphocytic Leukemia; B-Cell Lymphocytic Leukemias; B-Lymphocytic Leukemias; Leukemia, B-Cell Lymphocytic; Leukemia, B-Lymphocytic; Leukemias, B-Cell; Leukemias, B-Cell Lymphocytic; Leukemias, B-Lymphocytic; Lymphocytic Leukemia, B Cell; Lymphocytic Leukemias, B-Cell; B-Lymphocytic Leukemia; Leukemia, Lymphocytic, B-Cell; Lymphocytic Leukemia, B-Cell
Networked: 458 relevant articles (16 outcomes, 29 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Neoplasms (Cancer)
2. Lymphoma (Lymphomas)
3. Leukemia
4. B-Cell Lymphoma (Lymphoma, B Cell)
5. Non-Hodgkin Lymphoma (Lymphosarcoma)

Experts

1. Weiss, L: 5 articles (11/2007 - 01/2003)
2. Ishikawa, Masaaki: 4 articles (02/2013 - 05/2008)
3. Tobacman, Joanne K: 4 articles (01/2013 - 12/2010)
4. Bhattacharyya, Sumit: 4 articles (01/2013 - 12/2010)
5. Ikekita, Masahiko: 4 articles (05/2008 - 03/2002)
6. Abdul-Hai, A: 4 articles (11/2007 - 01/2003)
7. Slavin, S: 4 articles (11/2007 - 09/2003)
8. Yomogida, Shin: 3 articles (02/2013 - 05/2012)
9. Tomizawa, Ayako: 3 articles (02/2013 - 05/2012)
10. Jarjoura, David: 3 articles (09/2012 - 10/2007)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to B-Cell Leukemia:
1. Antigen Receptors (Antigen Receptor)IBA
2. rituximab (Mabthera)FDA Link
3. Immunotoxins (Immunotoxin)IBA
4. Monoclonal AntibodiesIBA
5. Immunoglobulin G (IgG)IBA
11/07/2015 - "B-cell leukemia is characterized by a high B-cell count and abnormal distribution of immunoglobulin G kappa (IgGκ) and lambda (IgGλ) light chains in serum. "
11/15/1988 - "This fact, together with its superior potency as an IT-A, suggests that RFB4 is the antibody of choice for preparing Fab'-As or IgG-As for in vivo therapy of human B-cell leukemias and lymphomas."
08/01/1986 - "We have subcloned the in vitro-adapted murine B cell leukemia, BCL1.B1, to obtain a variant that expresses both IgM and IgG1. "
07/01/1987 - "Previous studies have shown that a murine T-cell hybrid (B151K12) produces factor(s) that (i) induce immunoglobulin secretion by the B-cell leukemia line BCL1 and secondary anti-2,4-dinitrophenyl IgG synthesis in vitro by dinitrophenyl-primed B cells (TRF activity) and (ii) cause proliferation of the BCL1 cells [B-cell growth factor II (BCGF-II) activity]. "
01/17/2002 - "The following data support the concept of the immunomobilizing activity of the N-(2-hydroxypropyl)methacrylamide (HPMA) conjugates: (a) pre-treatment with free drugs (doxorubicin, cyclosporin A) accelerates the appearance of EL4 mouse T-cell lymphoma while a similar pre-treatment with doxorubicin-PHPMA induces limited but definitive mobilization of the host's defense mechanisms; (b) mice cured of EL4 mouse T-cell lymphoma, BCL1 mouse B-cell leukemia and 38C13 mouse B-cell lymphoma by injection of doxorubicin-PHPMA conjugate targeted with monoclonal antibodies (anti-Thy 1.2 for EL4, anti-B1 for BCL1 and anti-CD71 for 38C13) and re-transplanted with a lethal dose of the same cancer cells survive without any treatment considerably longer than control mice; (c) increased NK activity and anti-cancer antibody was detected only in animals treated with doxorubicin-PHPMA conjugate; and (d) considerably increased NK and LAK activity was seen in a human patient treated for generalized breast carcinoma with doxorubicin-PHPMA-IgG."
6. fludarabineIBA
7. Cyclosporine (Ciclosporin)FDA LinkGeneric
07/04/1990 - "Because cyclosporine and verapamil are known as inhibitors of the mdr1-encoded P-glycoprotein drug-efflux pump, and because the mdr1 and mdr3 genes are highly homologous, our data suggest that the mdr3 gene encodes a functional drug pump in B-cell lymphocytic leukemias. "
08/01/2004 - "The apoptotic effects were prevented by bongkrekic acid and low-dose cyclosporin A, which stabilize the mitochondrial membrane, and were associated with no evident change of inducible nitric oxide synthase (iNOS), B-cell leukemia/lymphoma-2 (Bcl-2) or Bcl-2-associated X protein (Bax) expression. "
01/17/2002 - "The following data support the concept of the immunomobilizing activity of the N-(2-hydroxypropyl)methacrylamide (HPMA) conjugates: (a) pre-treatment with free drugs (doxorubicin, cyclosporin A) accelerates the appearance of EL4 mouse T-cell lymphoma while a similar pre-treatment with doxorubicin-PHPMA induces limited but definitive mobilization of the host's defense mechanisms; (b) mice cured of EL4 mouse T-cell lymphoma, BCL1 mouse B-cell leukemia and 38C13 mouse B-cell lymphoma by injection of doxorubicin-PHPMA conjugate targeted with monoclonal antibodies (anti-Thy 1.2 for EL4, anti-B1 for BCL1 and anti-CD71 for 38C13) and re-transplanted with a lethal dose of the same cancer cells survive without any treatment considerably longer than control mice; (c) increased NK activity and anti-cancer antibody was detected only in animals treated with doxorubicin-PHPMA conjugate; and (d) considerably increased NK and LAK activity was seen in a human patient treated for generalized breast carcinoma with doxorubicin-PHPMA-IgG."
8. Isoantigens (Alloantigen)IBA
9. Doxorubicin (Adriamycin)FDA LinkGeneric
10. Dichlorodiphenyldichloroethane (DDD)IBA

Therapies and Procedures

1. Tissue Therapy (Cell Therapy)
2. Drug Therapy (Chemotherapy)
3. Transplants (Transplant)
4. Radioimmunotherapy
5. Immunotherapy